BRIEF published on 12/09/2025 at 18:35, 2 months 27 days ago Theraclion submits Sonovein to the FDA after significant progress FDA Theraclion SONOVEIN Varicose Veins HIFU
BRIEF published on 12/09/2025 at 18:35, 2 months 27 days ago Theraclion Submits Sonovein to FDA After Year of Key Achievements FDA Submission Clinical Evidence SONOVEIN Regulatory Achievements Varicose Vein Treatment
PRESS RELEASE published on 12/09/2025 at 18:30, 2 months 27 days ago Inside Information / Other news releases Theraclion announces FDA submission of Sonovein following a year of regulatory and clinical achievements. Key milestones in Europe and China also reached Clinical Milestones FDA Submission Theraclion SONOVEIN Regulatory Achievements
BRIEF published on 10/29/2025 at 18:35, 4 months 7 days ago Theraclion Announces 2025 Half-Year Financial Results and Strategic Progress Financial Results Revenue Growth Market Expansion U.S. Study Certification Progress
PRESS RELEASE published on 10/29/2025 at 18:30, 4 months 7 days ago Inside Information / News release on accounts, results Theraclion reports successful pivotal study, CE certification, GB 9706.1-2020 certification; 89% revenue increase and 23% operating loss reduction in 2025 half-year results Revenue Increase Operating Loss Reduction CE Certification Pivotal Study Theraclion
BRIEF published on 10/21/2025 at 18:35, 4 months 15 days ago Theraclion obtains crucial certification in China Medical Theraclion SONOVEIN® Focused Ultrasound Chinese Certification
BRIEF published on 10/10/2025 at 18:35, 4 months 26 days ago Monthly publication of Theraclion voting rights Share Capital Voting Rights Investment Euronext Growth Theraclion
PRESS RELEASE published on 10/10/2025 at 18:30, 4 months 26 days ago Inside Information / Other news releases Theraclion provides monthly update on total voting rights and shares. The French MedTech company uses focused ultrasound for non-invasive treatment. CE-marked platform SONOVEIN® targets varicose veins Voting Rights Shares Theraclion SONOVEIN Focused Ultrasound
BRIEF published on 09/15/2025 at 18:35, 5 months 20 days ago Theraclion Successfully Completes Pivotal Study with 96.8% Occlusion Rate FDA Clinical Trial Theraclion SONOVEIN® Varicose Veins
PRESS RELEASE published on 09/15/2025 at 18:30, 5 months 20 days ago Inside Information / Other news releases Theraclion announces successful U.S. FDA pivotal study showing 96.8% occlusion rate with Sonovein® for varicose vein treatment. Results support potential U.S. market entry Theraclion SONOVEIN® U.S. FDA Study Varicose Vein Treatment Occlusion Rate
Published on 03/05/2026 at 17:55, 1 hour 10 minutes ago ACCESS Newswire to Host Fourth Quarter and Year End Earnings Conference Call on March 19, 2026
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 13:40, 5 hours 25 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 17:57, 1 hour 8 minutes ago EQS-Adhoc: Delivery Hero SE may redeem convertible bonds in H1 2026 using proceeds from a USD 1.5bn increase of its term loans subject to certain conditions
Published on 03/05/2026 at 17:48, 1 hour 16 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/05/2026 at 17:45, 1 hour 19 minutes ago Swiss Prime Site announces the conversion price of its CHF 350 million green convertible bonds due 2032 and the outcome of the incentivized conversion invitation
Published on 03/05/2026 at 18:40, 25 minutes ago 2025 Full-year results FREY: a pan-European platform already creating value
Published on 03/05/2026 at 18:34, 30 minutes ago Mersen: Number of shares and voting rights as of February 28, 2026
